Rating

Moody's, Standard and Poor's and AM Best acknowledge the quality of Covéa as a sound counterparty.




Rating in a nutshell






Moody's opinion (2019)



Moody’s states that “the Aa3 IFSR on Covéa Cooperations reflects primarily Covéa’s outstanding level of capitalisation, the Group’s leading position in the French P&C market and the strong recognition of its three main brands (MAAF, MMA and GMF).” 

The agency points out that this rating “reflects the combined financial strength of the entire Covéa group“.




Standard and Poor's opinion (2018)



According to S&P Global Ratings, « the combined Covéa group of companies maintains robust operating performance while meeting the challenges of further consolidating its businesses and the unfavorable impact of certain regulations in France. »

The financial rating agency « anticipates that the Covéa group will maintain its strong competitive position. »




AM Best opinion (2018)



AM Best highlights that « Covéa’s strongest balance sheet assessment is underpinned by the group’s consolidated risk-adjusted capitalisation, which is categorised as strongest per Best’s Capital Adequacy Ratio (BCAR), a conservative and liquid investment portfolio, and a prudent reserving philosophy. »

The rating agency also underlines that « Covéa has a market leading position in the French non-life market, with a large, well-established member base and strong distribution capabilities. »



Attachments

  • 2017 Covéa Financial report

    pdf 1.01 MB Learn more
  • Synthesis of 2017 Covéa financial results

    pdf 1.49 MB Learn more
All documents



These contents may also be of interest to you